Literature DB >> 20890775

Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent.

Guilherme Suarez-Kurtz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20890775     DOI： 10.1007/s00228-010-0910-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  16 in total

1.  Characterization of the genetic profile of CYP2C19 in two South African populations.

Authors:  Britt I Drögemöller; Galen E B Wright; Dana J H Niehaus; Liezl Koen; Stefanie Malan; Danielle M Da Silva; Renate Hillermann-Rebello; Anthony M La Grange; Mauritz Venter; Louise Warnich
Journal:  Pharmacogenomics       Date:  2010-08       Impact factor: 2.533

Review 2.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Authors:  Alain Li-Wan-Po; Thierry Girard; Peter Farndon; Candy Cooley; James Lithgow
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

3.  Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

Authors:  D Dai; D C Zeldin; J A Blaisdell; B Chanas; S J Coulter; B I Ghanayem; J A Goldstein
Journal:  Pharmacogenetics       Date:  2001-10

4.  A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.

Authors:  Sarah C Sim; Carl Risinger; Marja-Liisa Dahl; Eleni Aklillu; Magnus Christensen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  Clin Pharmacol Ther       Date:  2006-01       Impact factor: 6.875

5.  Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.

Authors:  G Suarez-Kurtz; J P Genro; M O de Moraes; E B Ojopi; S D J Pena; J A Perini; A Ribeiro-dos-Santos; M A Romano-Silva; I Santana; C J Struchiner
Journal:  Pharmacogenomics J       Date:  2010-12-21       Impact factor: 3.550

Review 6.  Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.

Authors:  Rheem A Totah; Allan E Rettie
Journal:  Clin Pharmacol Ther       Date:  2005-05       Impact factor: 6.875

Review 7.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.

Authors:  Magnus Ingelman-Sundberg; Sarah C Sim; Alvin Gomez; Cristina Rodriguez-Antona
Journal:  Pharmacol Ther       Date:  2007-10-09       Impact factor: 12.310

8.  Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa.

Authors:  S Parikh; J-B Ouedraogo; J A Goldstein; P J Rosenthal; D L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2007-03-14       Impact factor: 6.875

9.  Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX'.

Authors:  Tom R Gaunt; Santiago Rodríguez; Ian Nm Day
Journal:  BMC Bioinformatics       Date:  2007-11-02       Impact factor: 3.169

10.  Global variation in CYP2C8-CYP2C9 functional haplotypes.

Authors:  William C Speed; Soonmo Peter Kang; David P Tuck; Lyndsay N Harris; Kenneth K Kidd
Journal:  Pharmacogenomics J       Date:  2009-04-21       Impact factor: 3.550
View more
  4 in total

1.  Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.

Authors:  Rania Abdelhedi; Nouha Abdelmoula Bouayed; Suad Alfadhli; Leila Abid; Ahmed Rebai; Najla Kharrat
Journal:  J Genet       Date:  2015-12       Impact factor: 1.166

2.  Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population.

Authors:  Rasmus Steen Pedersen; Mette Marie Hougaard Christensen; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2012-04-04       Impact factor: 2.953

3.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.

Authors:  Stuart A Scott; Katrin Sangkuhl; Alan R Shuldiner; Jean-Sébastien Hulot; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-02       Impact factor: 2.089

4.  Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.

Authors:  S Martis; I Peter; J-S Hulot; R Kornreich; R J Desnick; S A Scott
Journal:  Pharmacogenomics J       Date:  2012-04-10       Impact factor: 3.550
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.